CMRI is delighted by the NSW Government’s announcement about the establishment of Australia’s first commercial-scale viral vector manufacturing facility in the Westmead Health and Innovation District. The ability to manufacture high-quality (clinical grade) viral vectors in Australia is critically important for our gene therapy programs. It will accelerate the delivery of, and access to, life-saving new gene therapies developed in the CMRI labsContinue reading “New research facility to deliver life-saving medical technology in Western Sydney”
Research Collaboration Announced Between CMRI and DiNAQOR to Develop Novel, Cardiac Specific Capsids
CMRI has entered into a research collaboration with Zurich-based DiNAQOR, a genetic medicine platform company, to develop capsid gene therapy tools for treatment of both cardiovascular and kidney diseases.
Two Sydney siblings have become the first patients in the country to receive a novel gene therapy that has rescued their vision and holds hope for preventing them from going blind. The ocular gene therapy, LUXTURNA, is the world’s first approved gene replacement therapy for an inherited blinding eye condition and one of the firstContinue reading “Australian first gene therapy for childhood blindness”
Children’s Medical Research Institute (CMRI) was awarded multiple Medical Research Future Fund (MRFF) grants to help improve the lives of children living with genetic diseases. The MRFF, which is an initiative of the Australian Government, has funded research projects in cancer, gene therapy, and stem cell medicine at CMRI. Dr Anai Gonzalez-Cordero, head of theContinue reading “CMRI Awarded Multiple Medical Research Future Fund Grants”
Something went wrong. Please refresh the page and/or try again.
Get new content delivered directly to your inbox.